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Abstract: Older age and comorbidities in hemodialysis patients determines the use of tunneled
catheters as vascular access despite their reported clinical and mortality disadvantages. This prospec-
tive matched study analyzes the impact of permanent catheters on inflammation and mortality in
hemodialysis patients; We studied 108 patients, 54 with AV-fistula (AVF) and 54 with indwelling
hemodialysis catheters (HDC) matched by sex, age, diabetes and time under renal-replacement
therapy comparing dialysis efficacy, inflammation and micro-inflammation parameters as well as
mortality. Cox-regression analysis was applied to determine predictors of mortality, HDC patients
presented higher C-reactive-protein (CRP) blood levels and percentage of pro-inflammatory lympho-
cytes CD14+/CD16+ with worse dialysis-efficacy parameters. Thirty-six-months mortality appeared
higher in the HDC group although statistical significance was not reached. Age with a Hazard Ratio
(HR) = 1.06, hypoalbuminemia (HR = 0.43), hypophosphatemia (HR = 0.75) and the increase in
CD14+/CD16+ monocyte count (HR = 1.02) were predictors of mortality; elder patients dialyzing
through HDC show increased inflammation parameters as compared with nAVF bearing patients,
although they do not present a significant increase in mortality when matched by covariates. In-
creasing age and percentage of pro-inflammatory monocytes as well as decreased phosphate and
serum-albumin were predictors of mortality and indicate the main conclusions or interpretations.
Keywords: central venous catheter; fistula; hemodialysis; inflammatory status; mortality
1. Introduction
The vascular access (VA) for hemodialysis (HD) constitutes a critical issue in end-stage
renal failure (ESRF) patients. It is commonly accepted that native arterio-venous fistulae
(nAVF) are the elective VAs accordingly to their reduced infection ratios and better long-
term permeability [1,2] but, nevertheless, the use of indwelling venous central catheters
(VCCs) has increased progressively [3,4], especially in elderly comorbid patients [5].
The “fistula first” initiative reached success changing this trend6 and in recent years
large studies like the DOPSS (Dialysis Outcomes and Practice Patterns Study) have demon-
strated a reduction in hemodialysis catheter (HDC) use in a majority of participating
countries [6]. However, nAVFs are not always feasible: increasing age, greater cardiovascu-
lar comorbidity and the presence of diabetes mellitus in the dialysis patient population
yields significant percentages of patients nowadays dialyzing through indwelling VCCs [7].
Besides the “fistula first” initiative, several vascular access guidelines recommend
minimizing HDC use for chronic dialysis [8]. These best practice recommendations rely
in the evidence of VCC use in hemodialysis as an independent mortality predictor [9].
In fact, there is ample published evidence over the close relationship between HDC use
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and dialysis-related mortality [10,11]. The increase in mortality-ratio as compared with
nAVFs has been put in relation with an increase in invasive infections, low-quality renal
replacement delivery or a subclinical inflammatory state, associated with the VCC [12,13]
suggesting a determinant role in the patient’s inflammatory response as compared with
nAVFs [14]. It must be stated though that most studies analyzing morbimortality in VCC-
bound patients have an observational design, limiting their ability to address eventual
cause-and-effect relationships which abrogates the chance to eradicate nAVF-indication
bias. Moreover, the current evidence favoring nAVFs superiority over HDCs precludes the
implementation of randomized controlled trials (RCTs) comparing both VAs for ethical
reasons. In this context, we decided to start this paired study matching for variables
settled in the scientific literature for their impact on the inflammatory state and influence
in survival of hemodialysis patients with similar baseline profiles dividing them by the use
of HDC vs. nAVF.
Therefore, the objectives of the study are: (1) To compare the inflammation status
amongst hemodialysis patients with HDC vs. nAVF. (2) To compare survival between both
groups analyzing mortality-related factors.
2. Materials and Methods
2.1. The Scope of the Study
The study was carried out within the area of influence of the Nephrology Department
at Reina Sofía University Hospital of Córdoba (Spain). It was started started the 1st of July,
2016 with the baseline analysis of the sample concluding the 31st of December, 2019 with a
36 month follow up for the survival analysis.
2.2. Population, Sampling and Inclusion Criteria
A total of 398 patients were under hemodialysis therapy, from which 324 (81.4%)
carried a nAVF, 72 (18.1%) a tunneled HDC and 2 (0.5%) a prosthetic AVF.
Inclusion criteria for tunneled VCC were:
At least 3 months bearing an indwelling tunneled VCC.
No past history of catheter-related infection in the previous 3 months.
Not having been diagnosed with any systemic condition potentially associated with
an acute or chronic inflammatory state.
These criteria excluded nine patients, leaving a total of 65 eligible patients.
For nAVF patients eligible for matching, inclusion criteria were:
nAVF at least 3 months in use.
No past history of nAVF-related infection within the last 3 months.
Not having been diagnosed with any systemic condition potentially associated with
an acute or chronic inflammatory state.
2.2.1. Dialysis Scheme
Patients received hemodialysis as prescribed per clinical and analytical requirements,
on a three-weekly basis, 3 to 5 h per session, using 5008 S or 5008 Cordiax devices (Fresenius
Fresenius Medical Care, Bad Homburg, Germany) equipped with OCM biosensors (On-
line clearance monitoring), non-invasively measuring ionic dialisance equivalent to the
clearance of urea (K). The systematic register of K multiplied by the elapsed time allows
the procurement of Kt, which constitutes a mean to effectively measure the provided dose
of dialysis, expressed in liters, and the Kt/V (clearance of urea*time in dialysis/Urea
distribution volume).
All the subjects had sinthetic membrane dialyzers (Helixona®, Fresenius Medical Care,
Bad Homburg, Germany). Indwelling HDCs were made of polyuretane Equistream® (Bard
Access Systems, Salt Lake City, UT, USA). Forty-nine (91%) patients had the CVCt placed
in the right internal jugular vein and 5 (9%) in the left internal jugular vein.
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2.2.2. Nursing Care of HDCs
Nursing care and management of HDCs was similar for all the patients. Connection
and disconnection procedures to the extracorporeal circuit lines followed the recommen-
dations from the Vascular Access Guidelines of the Spanish Society of Nephrology [8].
These procedures emphasized the prevention of infections (sterile single-use material use,
surgical-mask wearing for patient and nurse during connection and disconnection, and in
every needed HDC handling during the dialysis session, and 1% sodium-heparine sealing
as well as 2% aqueous clorhexidine antiseptic cleansing for the skin exit orifice).
2.3. Study Design
Prospective observational matched cohort study of patients with indwelling HDCs or
nAVFs, in concordance with the most influential covariables regarding the inflammatory
status and mortality in these patients: age, sex, time in hemodialysis (from the moment of
being established in the therapy up to the beginning of the study) and Diabetes Mellitus
(DM). Matching for age was elected for ±10 years and for time-in-dialysis ±60 months.
The matching was computerized with the Nephrology Departmnet database, curating data,
verifying one-by-one matches and checking equality of the groups for adjusting covariables.
Baseline inflammatory and clinical parameters for the patients were determined. Later,
follow up was carried for survival analysis. Follow-up concluded with the death of the
subject or the termination of the study after 36 months.
2.4. Study Variables and Labs
Inflammation, microinflammation and mortality markers were taken as variables of
outcome.
Inflammation was determined by the following parameters: C-reactive-protein (CRP),
Albumin and Ferritin. Microinflammation was measured with the percentage of pro-
inflammatory circulant monocyte subpopulation in peripheral blood CD14+/CD16− and
CD14+/CD16+.
Cell Cultures
Immunolabelling and flow cytometry were performed in whole blood to avoid cen-
trifugation and washing steps which can lead to artifactual platelet activation. Aliquots
of whole blood (100 µL) were incubated with peridinin chlorophyll protein-conjugated
monoclonal anti-CD14 (M5E2), FITC-conjugated anti-CD16 (3G8) and isotype matched
controls for 20 min (min) at room temperature (RT). Thereafter, samples were fixed and the
red cells lysed by the addition of 500 µL of FACS-Lyse solution (Becton Dickinson). Both
antibodies and the appropriate isotype controls were purchased from BD Biosciences (San
Jose, CA). Flow cytometry was performed on a FACSCalibur (BD Biosciences) using Cel-
lQuest. Monocytes were identified based on their forward and side scatter characteristics.
For each measurement, a minimum of 2500 monocytes were collected. The percentage of
CD14+/CD16− and CD14+/CD16+ monocytes was calculated by subtracting nonspecifi-
cally stained cells, as identified in the isotype control histogram.
Last hemodialysis session data (Blood Pressure, Kt/V, Kt, length of dialysis procedure,
blood flow, volume of dialyzed blood per session, dialysis modality (On-Line Hemodial-
filtration vs. conventional hemodialysis)) were collected simultaneously with the blood
sampling to determine the degree of the inflammation as well as other parameters such as
Hemoglobin and Serum Phospate and Potassium and Parathyroid Hormone. Comorbidity
was also estimated by the Charlson Comorbidity Index (CCI). NAVF-related infections were
documented as well as any-cause hospitalization periods. Total time with an indwelling
HDC was also registered.
Furthermore, in the patients with CVCt, the following were collected: the time they
had been with the catheter, episodes of dysfunction (Blood Flow < 300 mL/min), intra-
luminal fibrinolytic treatments and catheter replacements; and in patients with AVF, the
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following was collected: blood recirculation > 15%, (BTM Blood Temperature Monitor) and
a sustained decrease in the Kt index (OCM biosensor) for the detection of stenosis [8].
2.5. Legal and Ethical Issues
All patients were informed about the purpose of the study and signed an informed
consent sheet before entering into the study. Favorable Córdoba Ethics Committee approval
was obtained in advance (3 December 2015, Ref. 2999).
2.6. Statistical Analysis
Qualitative variables were represented as frequency charts and their percentages
whilst quantitative variables were expressed as mean ± standard deviation or median
and interquartilic range, depending on their normal-non normal distribution after con-
trasting with the Kolmogorov–Smirnov test. Means were compared by Student’s t test
whilst non-parametric Mann–Whitney’s test was employed when applicable. Survival was
estimated by the Kaplan–Meyer test and compared between groups using the Log Rank
test. Proportional Risks Cox Regression Multivariate Analysis was carried for the time to
the outcome variable as well as raw Hazard Ratio (HR) for each explanatory variable. An
adjusted model was created from the statistically significant variables. The probability of
an α error of below 5% (p < 0.05) was considered statistically significant for all the statistical
analyses. The confidence interval was calculated at 95%. For the statistical analysis, IBM
SPSS Statistics 22.0 software (IBM, Chicago, IL, USA) was used.
3. Results
3.1. Study Sample Description
Fifty-four patients with indwelling HDC were matched with another 54 patients
bearing nAVFs. A final sample including 108 patients was obtained. Table 1 represents
data with matching covariables and baseline etiology from both groups of patients.
Table 1. Baseline values for the paired variables and the base aetiologies of the total number of patients and of both groups
of patients.
Total Patients (n = 108) AVF (n = 54) VCC (n = 54) p-Value
Age (years) 79 (70–83) 79 (70–83) 79.5 (69–84) 0.848
Sex (women) 60 (56%) 30 (56%) 30 (56%)
Time on HD regimen (months) 62.6 ± 39.5 62.3 ± 39.6 62.8 ± 39.8 0.952
Presence of diabetes 42 (39%) 21 (39%) 21 (39%)
Dialysis Technique Mode
HD mode 80 (74%) 29 (31%) 51 (69%) *
OL-HDF 28 (26%) 25 (89%) 3 (11%) *
CKD aetiology
CKD of unknown origin 45 (42%) 25 (46%) 20 (37%) *
Diabetic nephropathy 22 (20%) 11 (20%) 11 (20%) *
Glomerulonephritis 11 (10%) 5 (9%) 6 (11%) *
Polycystic 11 (10%) 5 (9%) 6 (11%) *
Interstitial 7 (7%) 3 (6%) 4 (8%) *
Vascular 4 (4%) 2 (4%) 2 (4%) *
Other 8 (8%) 3 (6%) 5 (9%) *
Abbreviations: AVF: autologous arteriovenous fistula; VCC: venous central catheter; HD: hemodialysis; OL-HDF: on-line hemodiafil-
tration; CKD: chronic kidney disease. Note: Age: median and Q1–Q3; Time in HD: mean ± standard deviation; CKD aetiology: in the
columns of patients with AVF and CVCt, the percentages with respect to the total number of patients in each group. * No interest in
statistical comparison.
HDCs were carried by the patients a median of 32 months (Q1 = 18 months and
Q3 = 60 months). No relationship was found between this time and the rest of the variables.
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There were no catheter-related bacteriemias during the study although it was sus-
pected in two hospital admissions due to fever of unknown origin. There were 30
(median = 4, range between 2 and 7) episodes of dysfunction due to blood flow deficit
(<300 mL/min) that required 20 intraluminal fibrinolytic treatments with urokinase® in
patients with CVCt.
In patients with AVF, there were no episodes of blood recirculation or a sustained
decrease in Kt, so there was no evidence of any alteration that would suggest stenosis of
the fistulas.
3.2. Inflammation and Microinflammation Parameters
When comparing seldom inflammatory parameters amongst groups, patients carry-
ing HDCs showed a statistically significant increase in CRP and serum Ferritin, as well
as a decreased serum albumin, as compared with nAVF bearing patients. Respecting
microinflammation, the percentage of proinflammatory monocytes CD14+/CD16+, was
significantly increased in patients with HDCs as compared to patients with nAVFs as is
shown in Table 2.
Table 2. Comparison between patients with AVF and VCC of the variables of inflammation and microinflammation.
Total Patients (n = 108) AVF (n = 54) VCC (n = 54) p-Value
CRP (mg/L) 4.9 (2.4–11.4) 3.4 (1.5–7.9) 7.4 (3.6–17.6) 0.002
Serum albumin (g/dL) 3.7 (3.4–3.9) 3.8 (3.5–3.9) 3.7 (3.3–3.9) 0.078
Serum ferritin (ng/dL) 540.8 ± 353.2 455.2 ± 352.7 625.5 ± 335.9 0.011
% CD14+/CD16+ monocytes 47.4 ± 12.3 43.6 ± 12.7 51.2 ± 10.9 0.001
% CD14+/CD16- monocytes 26.8 ± 12.3 27.4 ± 13.1 26.1 ± 11.7 0.595
Abbreviations: CRP: C-reactive protein; CRP and serum albumin: median and Q1–Q3; Serum ferritin, %CD14+/CD16+ monocytes,
%CD14+/CD16- monocytes: mean ± standard deviation (SD).
In Supplementary Figure S1, we represent flow cytometry charts after determining
monocytes and CD14+/CD16+ expression with the dot-diagram in HDC and nAVF bear-
ing patients.
3.3. Analytic Values, Dialysis Efficacy, Comorbidity and Hospital Admissions
Patients with HDcs had a lower hemoglobin (Hb) and higher serum phosphate and
potassium, the latest showing statistical significance. Patients with CVCt had lower levels
of systolic blood pressure and hemoglobin and higher serum phosphorus and potassium,
although with significant differences only for potassium. PTH levels were higher in patients
with CVCt, although without significant differences.
nAVF bearing patients presented better dialysis efficacy parameters, reaching sta-
tistical significance in the treated blood volume per session, dialysis arterial blood flow,
Kt/V and Kt, although 91% of the patients from both groups had a Kt/V > 1.3; (99% of
nAVF and 92% of HDC). When the Kt/V was compared amongst diabetic and non-diabetic
patients, there were no significant differences (1.92 ± 0.46 vs. 1.81 ± 0.48, p = 0.261) but
reaching significance the differences between men and women (2.0 ± 0.48 vs. 1.73 ± 0.41,
respectively, p = 0.003). Mean Kt in women was 52.33 ± 8.59 L with a 95% CI (50.03–54.63).
In men, it was 53.39 ± 9.16 L with 95% CI (50.72–56.05).
There were no differences in comorbidity between groups and despite a higher total
number of hospital-days in HDC carrying patients, it did not reach statistical significance
as may be seen in Table 3.
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Table 3. Comparison between patients with AVF and VCC of the analytical values studied, dialysis efficacy variables,
comorbidity and days of hospitalization.
Total Patients (n = 108) AVF (n = 54) VCC (n = 54) p-Value
SBP (mmHg) 140.1 ± 28 145.2 ± 27 135 ± 28 0.069
DBP (mmHg) 71.3 ± 17 71.7 ± 14 71 ± 19 0.806
Haemoglobin (g/dL) 11.1 ± 1.2 11.4 ± 1 10.9 ± 1.5 0.55
Phosphate (mg/dL) 4.0 ± 1.0 3.8 ± 1.0 4.2 ± 1.1 0.083
Potassium (mEq/L) 5.1 ± 0.8 4.8 ± 0.8 5.4 ± 0.8 0.000
PTH pg/mL 229.6 (141–365) 223.6 (138–346) 276.2 (142–412) 0.588
HD session duration (minutes) 250 (245–250) 250.3 (245–250) 249.3 (245–252) 0.564
Volume of treated blood (liters) 94.1 ± 19.4 102.3 ± 19.5 85.8 ± 15.4 0.000
Blood flow (mL/min) 388.7 ± 75.8 421.2 ± 75.2 354.9 ± 54.1 0.000
Kt (liters) 52.8 ± 8.9 57.5 ± 7.3 48.4 ± 7.8 0.000
Kt/V 1.9 ± 0.5 2.0 ± 0.5 1.74 ± 0.5 0.005
CCI (points) 7 (6–9) 7 (6–9) 7 (6–9) 0.899
Hospitalization (days) 8 (0–19) 7 (0–18.2) 9 (0–25) 0.526
Abbreviations: AVF: autologous arteriovenous fistula; VCC: venous central catheter; SBP: Systolic Blood Pressure; DBP: Diastolic Blood
Pressure; PTH: parathyroid hormone; CCI: Charlson Comorbidity Index; HD: haemodialysis; Kt: urea clearance*dialysis time; Kt/V: urea
clearance*dialysis time/urea volume of distribution. SBP, DBP, Haemoglobin, phosphorus, potassium, volume of blood treated/session,
dialysis blood flow, Kt, Kt/V: mean ± standard deviation. PTH, Duration of the HD session, ICC, days of hospitalisation: median and
Q1–Q3.
3.4. Survival Analysis
There were 48 deaths (44.4%) during follow up (25 women and 23 men). Global
and vascular access-specific group causes of death are described in Table 4. No patient
required a kidney transplant. No study patients were censored for transplantation during
the 36-month follow-up period.
Table 4. Causes of death according to vascular access.
Total Patients (n = 108) AVF Deaths(n = 21)
VCC Deaths
(n = 27)
Undetermined cause 10 (21%) 6 (29%) 4 (14%)
Septicemia 5 (11%) 1 (4%) 4 (14%)
Other causes of heart failure 5 (11%) 4 (19%) 1 (4%)
Stroke 5 (11%) 1 (4%) 4 (14%)
Mesenteric infarction 4 (8%) 1 (4%) 3 (11%)
Malignant disease 3 (6%) 1 (4%) 2 (7%)
Other bleeds 3 (6%) 2 (10%) 1 (4%)
Lung infection 3 (6%) 1 (4%) 2 (7%)
Treatment interruption 2 (4%) 1 (4%) 1 (4%)
CRP of unknown origin 2 (4%) 2 (10%)
Epileptic status 1 (2%) 1 (4%)
Acute myocardial infarction 1 (2%) 1 (4%)
Cachexia 1 (2%) 1 (4%)
Subdural haematoma 1 (2%) 1 (4%)
Septic shock 1 (2%) 1 (4%)
Peritonitis 1 (2%) 1 (4%)
Abbreviations: AVF: autologous arteriovenous fistula; VCC: venous central catheter. Note: in the columns for AVF and CVVCt, percentages
are indicated with respect to the total number of deceased patients in each group.
With the Log Rank test, differences were non-significant between nAVF and HDC groups
despite there being an 11.1% higher 36-month mortality in the HDC group (Figure 1A).
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Figure 1. (A–D). Kaplan Meyer curves, comparing survival according to venous access, gender,
diabetes mellitus and serum phosphorus levels (<4 mg/dL or >4 mg/dL) using the Log Rank test.
The percentages of deaths at 12, 24, 36 months are described for patients with AVF and VCC.
Moreover, there were neither significant differences in survival between men and
women (Figure 1B) nor amongst diabetics and non-diabetics (Figure 1C).
Serum phosphate (P) was split into two groups by the median (4 mg/dL): patients with
p < 4 mg/dL, and patients with p > 4 mg/dL, and when compared, survival was greater
with p > 4 mg/dL (Figure 1D), with statistically significant differences (Log Rank = 5.274,
p = 0.022).
The lower part of Figure 1 shows deaths and death percentages at 12, 24 and 36 months.
3.5. Cox Regression
Table 5 shows raw and adjusted all-variable Cox regression.
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Table 5. Cox regression: crude and adjusted estimates for the study variables.
Crude Estimate Adjusted Estimate
HR 95% CI p-Value HR 95% CI p-Value
Age 1.064 1.024–1.106 0.001 1.056 1.015–1.098 0.007
Sex (ref. woman) 1.174 0.666–2.069 0.579
Vascular access (ref. AVF) 1.458 0.824–2.579 0.195
Diabetes (ref. absence of
diabetes) 0.855 0.476–1.533 0.598
SBP 0.998 0.988–1.008 0.673
DBP 0.984 0.967–1.003 0.094
Kt/V 1.314 0.735–2.349 0.357
Kt 0.974 0.944–1.005 0.094
HD session duration 0.989 0.970–1.008 0.249
Volume of treated blood 0.995 0.980–1.010 0.520
Blood flow 1.000 0.996–1.004 0.928
CRP 1.005 0.995–1.016 0.306
Serum albumin 0.466 0.244–0.890 0.021 0.435 0.224–0.845 0.014
Serum ferritin 1.001 1.000–1.001 0.113
CCI 1.165 1.023–1.327 0.021
HD weather 1.005 0.998–1.012 0.165
% CD14+/CD16+ 1.012 0.989–1.036 0.317 1.022 0.997–1.047 0.089
% CD14+/CD16- 0.994 0.972–1.018 0.635
Haemoglobin 0.932 0.749–1.159 0.534
Serum phosphorus 0.687 0.520–0.909 0.009 0.750 0.569–0.989 0.041
Serum potassium 0.832 0.586–1.180 0.302
PTH 1.000 0.999–1.001 0.507
Length of stay 0.996 0.976–1.016 0.684
Dialysis mode 0.706 0.352–1.418 0.328
Abbreviations: HR: hazard ratio; CI: confidence interval; AVF: autologous arteriovenous fistula; SBP: Systolic Blood Pressure; DBP: Diastolic
Blood Pressure Kt: urea clearance*dialysis time; Kt/V: urea clearance*dialysis time/urea volume of distribution; HD: haemodialysis; CRP:
C-reactive protein; CCI: Charlson Comorbidity Index.; PTH: parathyroid hormone.
Univariant analysis showed significance for age, serum albumin, heart failure and P.
Adjusted model analysis, kept significance for age, serum albumin, P and the percentage
of proinflammatory monocytes CD14+/CD16+.
The increase in age and the percentage of CD14+/CD16+ proved to be mortality
predictors, being that P and albumin increase protective variables. In this sense, for
each one-year increase mortality showed a 5.6% growth whilst for each g/dL of serum
albumin decrease, mortality increased 5.6 times. For each 1% increase in the number of
CD14+/CD16+, there was a 2.2% increase in mortality and for every 1 mg/dL decrease in
serum phosphus, mortality increased 2.5 times.
4. Discussion
We designed this study with the aim of comparing inflammation amongst hemodial-
ysis patients with indwelling HDCs with nAVF-carrying patients. Patients with HDCs
presented an increase in parameters measuring inflammation and microinflammation as
compared with patients bearing a nAVF. Accordingly, CRP and serum ferritin but not
albumin levels were significantly higher. Previous observational studies have already
related CVCs as a significant influence in the inflammatory state of HD patients [15,16].
Wystrychowski et al. [17], have shown an improvement in inflammatory markers when
HDC-dialyzing patients were changed to nAVF as dialysis access and the opposite.
Apart from classic humoral inflammation markers we have performed microinflam-
mation studies, expressed by proinflammatory monocyte activation where we found a
significant increase in the percentages of the CD14+/CD16+ subpopulation in HDC-bearing
patients as compared to the ones with nAVF. Even though dialysis patients show elevated
percentages of these cells respective from healthy subjects [18,19], CVCs seemingly increase
cell inflammation compared with nAVFs. Coli et al. have already demonstrated an increase
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in both humoral and cellular inflammatory markers in HDC dialyzing patients respective
of nAVFs confirming our results as catheters per se behave as independent inflammation
promoters in HD patients [20], possibly related to biofilm formation in the inner catheter
surface days after its insertion, as several studies have pointed out [21].
Although some authors have associated inflammation in patients with indwelling
CVCs to catheter-related infections [22], only two patients in our group had suspected line
infection with documented catheter-related bacteriemia supporting the role of catheters -in
the majority of the non-infected catheters- in the subyacent inflammatory state as shown
by Goldstein et al. [23].
Regarding the few complications recorded in patients with CVCt, taking into account
that HD through a catheter has been associated with different complications, it should be
noted that no deep vein stenosis was observed and the episodes of dysfunction were minor,
being these results are consistent with those shown by Poinen K et al. (2019) [24] finding
that CVC patients older than 79 have fewer catheter-related complications than younger
populations [25]. Regarding the low number of infectious episodes in our cohort, we must
state the complete adherence to the catheter-care guidelines in our patients [8], which we
estimate crucial. The effect of the care provided in the prevention of infections—accounting
for manipulation supported by the catheters along their use, especially when dysfunction
appears—, tend to inadvertently pass in the majority of the studies [26], mostly in large
population series, being difficult to find bibliography over the influence of nursing care in
the prevention of catheter-related bacteriemias [27].
Looking into dialysis efficacy, patients dialized through a nAVF had better results than
those with CVCs in all parameters despite different session length. In general, accordingly
with previous studies [28,29], patients dialyzed through nAVFs receive better extrarenal
depuration than those with HDCs. Nevertheless, in our sample 92% of HDC patients
had a Kt/V > 1.3 and a Kt in men and women above 45 and 50 L, respectively as per
recommended objectives of dialysis adequacy [30]. In addition, both groups of patients
had a mean session duration of 250 min, a time higher than the recommendations of the
European and Spanish guidelines (minimum of 12 h a week), which may explain the
suitable analytical and efficacy parameters of the dialysis of the majority of the population
studied, regardless of the VA used. The longer duration of the HD session has been related
to better clinical results and higher survival even independently of Kt/V [31], with a
session lasting less than 4 h being associated with a 42% increase in mortality [32]. Clearly
then, there was no “underdialysis” which could explain this variable´s absent influence in
mortality in opposition with other authors’ descriptions [33]. The ICC had similar scores
within both groups, supporting the study´s results indicating appropriate matching for the
proposed purposes. Taking into account that age, sex and comorbidity play an essential
role in Health-Related Quality of Life (HRQoL) in HD patients [34], it would have been
interesting to compare this variable between both groups, taking advantage of the matching
of the same, since in previous studies worse HRQoL has been reported in patients who
underwent dialysis using a CVC compared to those who did so using an AVF, although
patients with a catheter had greater comorbidity [35]. We neither found differences in total
hospital days during follow up, although HDC-carrying patients had greater hospital days
unlike recent communications stating more episodes in shorter periods [36].
Another outcome was based on the comparison between both group´s survival and
the analysis of factors impacting mortality amongst groups. When mortality was di-
rectly compared, patients with CVC´s presented proportionally more deaths at 12, 24
and 36 months, with an 11% excess mortality at the end of the follow up despite non
statistically significant differences found due to the small sample size. There were neither
differences in mortality between men and women nor between diabetic and non-diabetics.
On the contrary, patients with serum-phosphate <4.0 mg/dL had greater mortality, with
significant differences when compared with patients having >4.0 mg/dL. In the raw Cox
proportional risks analysis, age, serum albumin, ICC and serum phosphate showed statisti-
cal significance. After adjusting for all variables, increasing age, CD14+/CD16 monocytes
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percentage, decreased serum albumin and phosphate remained in the model as predictors
of mortality.
Increasing age and inflammatory condition as well as hypoalbuminemia and hy-
pophosphatemia have been associated with mortality in dialysis patients by different
authors and have also been postulated as independent interrelated predictors [37]. In this
sense, in our study, VA did not work as a mortality predictor after adjusting for all vari-
ables. The explanation for these findings may be put in relation with the basal homogeneity
between both groups of patients and in their age (75% > 70 years-old). When adjusting as
possible baseline conditions amongst nAVFs with HDCs, VA does not seem to be the direct
cause of mortality but an inflammation inducer indirectly responsible for malnutrition and
greater mortality [38].
During the decade 2000–2010, several studies proved a greater mortality for patients
with indwelling CVCs as compared to nAVF bearing patients [10–12,39,40] although there
was a European investigation by Di Iorio et al. [41] claiming absent differences in mortality
after adjusting by age, sex, poor nutritional status, diabetes, hemoglobin, albumin and
other comorbidities. Later, Ravani et al. [42] in 2013, developed a meta-analysis including
62 studies totaling 586,337 patients showing an excess of all-cause mortality in HDC
patients versus the group dialyzing through nAVFs recognizing a high risk of selection
bias as a major weakness of their work. More recently, De Clerk et al. [43] in another
European study found a 39% reduction in mortality ratio in nAVF-related hemodialysis
compared to CVCs associated hemodialysis that—nevertheless—lost statistical significance
after correcting for variables such as serum albumin, CRP or hemoglobin which suggests
non-vascular access related mortality behind this study. Moreover, the cohort of patients
included in this work presented a low ratio of catheter-related bacteriemias supporting the
cardinal role of a continued adherence to CVC management best practice guidelines and of
specialized dialysis nursing cares in this setting.
It may be hypothesized that as currently published studies approaching the involve-
ment of CVCs in the mortality of hemodialysis patients are based in observational studies,
this makes them prone to fall into a selection bias as there is a lack of better evidence
coming from published randomized controlled trials absent so far in the literature.
It is possible that many patients end up with a HDC vascular access instead of a nAVF
due to their more compromised condition. In this sense, Quinn et al. [44] found that the
excess in mortality associated with CVCs could be not related to direct VA complications
but to residual confusion, non-measured comorbidities or treatment-selection bias.
Moreover, Brown et al. [45] observed that incident hemodialysis patients starting
through a HDC due to nAVF failure had a decreased mortality as compared to straight
forward HDC starters arguing that these could explain up to two thirds of the benefit in
mortality recorded in nAVF-based dialysis. This suggests that there are several factors
linked to patients with a specific clinical profile that end up with an indwelling HDC due
to the difficulties in nAVF creation [46].
Besides this, the increase in nAVF use—even in patients at risk of nAVF insufficient
maturation—has yielded a greater chance of nAVF primary failure adding up complications
and hospital days for this reason and therefore, catheter use continues to be a necessity in
elder or comorbid patients unsuitable for nAVF creation or maturation making compulsory
individualized nAVF referrals [47].
As main limitations of this study we must point out the fact of being a single center
work which, added to the matching by mortality-influential variables, has enabled a small
sample size. Nevertheless, this limitation also constitutes a main strength providing a very
homogeneous cohort and the opportunity to compare two groups of patients with very
similar baseline features—differing only in the VA—which undoubtedly strengthens its
internal validity.
Int. J. Environ. Res. Public Health 2021, 18, 7605 11 of 13
5. Conclusions
As a summary, we can conclude that the patients dialyzing through a tunneled CVC
present a high degree of inflammation compared to the patients dialyzing through a nAVF.
However, VA does not seem to directly influence mortality when patients are matched by
the same covariables, at least in this group of patients. In this sense, in our department we
continue referring all patients for nAVF creation although in elder patients with a short
life-expectancy or severe comorbidities complicating nAVF creation or maturation, the
use of HDCs must not be discarded. In these cases, it must be done with an emphasis on
the prevention of eventual infectious complications and under a strict follow up of best
catheter care and handling recommendations from specialized guidelines.
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